Table 5.
Retrospective studies and prospective clinical trials in AS
| Author | Year | N | Treatment regimen | ORR | mTTP/mPFS (months) | mOS (months) |
|---|---|---|---|---|---|---|
| Retrospective studies | ||||||
| Schlemmer et al.(8) | 2008 | 32 | Single-agent P (weekly or q3w) | 62% | 7.6 | NI |
| Stacchiotti et al.(11) | 2011 | 25 | Gemcitabine | 64% | 7.0 | 17.0 |
| Penel et al.(24) | 2012 | 149 | - Ant-based (46.9%) -P (31.5%) -Other (Sorafenib, platinum-based, vinorelbine, ifosfamide etc.) |
Ant-based – 30.9% | Ant-based – 3.9 | 11.0 |
| P – 45.5% | P – 5.6 | |||||
| Overall | 3.2 | |||||
| Italiano et al.(23) | 2012 | 117 | Single-agent P (64%)/Single-agent Dox (36%) | Dox – 29.5% | Dox – 3.0 | Dox – 5.5 |
| P – 53% | P – 5.8 | P – 10.3 | ||||
| Overall | 4.9 | 8.5 | ||||
| D’Angelo & Munhoz et al. | 2014 | 119 | - Ant-based - Tax-based -Other (Sorafenib, platinum-based, vinorelbine, ifosfamide etc.) |
Ant-based - 30% | 3.4 | 12.0 |
| Tax-based - 31% | 3.6 | 11.6 | ||||
| Overall - 30% | 3.9 | 12.1 | ||||
| Prospective clinical trials | ||||||
| Penel et al. (27) | 2008 | 30 | WP | 19% | 4.0m | 8.0m |
| Maki R et al.(26) | 2009 | 37 | Sorafenib | 14% | 3.8m | 14.9m |
| Ray-Coquard et al (10) | 2012 | 41 | Sorafenib | 14.6% | 2.0m | 9.7m |
| Agulnik et al. (25) | 2013 | 23 | Bev | 9% | 3.0m | 13.2m |
| D’Angelo et al. (29) | 2014 | 16 | Trebananib (AMG386) | 0% | 1.7m | 7.0m |
| Penel et al. (28) | 2014 | 50 | WP | 50% | 6.8m | 19.5m |
| WP + Bev | 40% | 6.9m | 15.9m | |||
N – total number of patients/Dox – doxorubicin/P – paclitaxel/Ant-anthracyclines/Tax-taxanes/PS – performance status/ORR – objective response rate/mTTP – median time to tumor progression/mOS – median overall survival/Prog. factors – prognostic factors associated with survival on multivariate analysis/WP – weekly paclitaxel/Bev – Bevacizumab/ORR – objective response rate/SD – stable disease rate/mPFS – median progression free survival in months/mOS – median overall survival in months